Остро возникшие симптоматические эпилептические приступы при проведении трансплантации гемопоэтических стволовых клеток

Одним из осложнений трансплантации гемопоэтических стволовых клеток у пациентов онкогематологического  профиля являются остро возникшие симптоматические  эпилептические приступы. Этиологические факторы, приводящие к развитию данного осложнения, отличаются от  таковых в общей популяции, при этом значимость каждого  из них различна в зависимости от сроков после  трансплантации. В статье проанализированы данные  литературы, посвященной роли лекарственных препаратов,  метаболических нарушений и инфекционных осложнений, а  также структурной патологии вещества головного мозга в  развитии симптоматических эпилептических приступов у  больных онкогематологического профиля. Рассмотрены их  клинические особенности и возможное прогностическое  значение их развития у пациентов, перенесших  трансплантацию гемопоэтических стволовых клеток.

1. Афанасьев Б.В., Зубаровская Л.С., Моисеев И.С. Аллогенная трансплантация гемопоэтических стволовых клеток у детей: настоящее, проблемы, перспективы. Российский журнал детской гематологии и онкологии. 2015; 2 (2): 28–42. https://doi.org/10.17650/2311-1267-2015-2-2-28-42.

2. Afanasyeva K.S., Barabanshchikova M.V., Bondarenko S.N., et al. Indications for hematopoietic stem cell transplantation. Cellular Therapy and Transplantation. 2019; 8 (4): 101–45. https://doi.org/10.18620/ctt-1866-8836-2019-8-4-101-145.

3. Паровичникова Е.Н., Савченко В.Г. Российские многоцентровые исследования по лечению острых лейкозов. Терапевтический архив. 2019; 91 (7): 4–13. https://doi.org/10.26442/00403660.2019.07.000325.

4. Bondarenko S.N., Moiseev I.S., Slesarchuk O.A., et al. Allogeneic hematopoietic stem cell transplantation in children and adults with acute lymphoblastic leukemia. Cellular Therapy and Transplantation. 2016; 5 (2): 12–20. https://doi.org/10.18620/1866-8836-2016-5-2-12-20.

5. Паина О.В., Рахманова Ж.З., Кожокарь П.В. и др. Результаты аллогенной трансплантации гемопоэтических стволовых клеток от совместимого неродственного и родственного гаплоидентичного донора у детей с младенческим лейкозом высокой группы риска в первой и второй ремиссии. Вопросы гематологии/ онкологии и иммунопатологии в педиатрии. 2020; 19 (2): 30–7. https://doi.org/10.24287/1726-1708-2020-19-2-30-37.

6. Kang J.M., Kim Y.J., Kim J.Y., et al. Neurologic complications after allogeneic hematopoietic stem cell transplantation in children: analysis of prognostic factors. Biol Blood Marrow Transplant. 2015; 21 (6): 1091–8. https://doi.org/10.1016/j.bbmt.2015.02.007.

7. Zhang X.H., Xu L.P., Liu D.H., et al. Epileptic seizures in patients following allogeneic hematopoietic stem cell transplantation: a retrospective analysis of incidence, risk factors, and survival rates. Clin Transplant. 2013; 27 (1): 80–9. https://doi.org/10.1111/ctr.12000.

8. Полушин А.Ю., Владовская М.Д., Моисеев И.С. и др. Проблема неврологических осложнений после неродственной трансплантации гемопоэтических стволовых клеток и таргетной терапии при злокачественных гематологических заболеваниях. Сборник материалов научной конференции XXI «Давиденковские чтения». СПб.: Человек и его здоровье; 2019: 256–8.

9. Cordelli D.M., Masetti R., Zama D., et al. Etiology, characteristics and outcome of seizures after pediatric hematopoietic stem cell transplantation. Seizure. 2014; 23 (2): 140–5. https://doi.org/10.1016/j.seizure.2013.11.003.

10. Lipatova L.V., Rudakova I.G., Sivakova N.A., Kapustina T.V. Acute symptomatic epileptic seizures and status epilepticus. Zh Nevrol Psikhiatr Im S S Korsakova. 2015; 115 (4): 24–9 (in Russ.) https://doi.org/10.17116/jnevro20151154124-29.

11. Annegers J.F., Hauser W.A., Lee J.R, Rocca W.A. Incidence of acute symptomatic seizures in Rochester, Minnesota, 1935–1984. Epilepsia. 1995; 36 (4): 327–33. https://doi.org/10.1111/j.1528-1157.1995.tb01005.x.

12. Costello D.J., Cole A.J. Treatment of acute seizures and status epilepticus. J Intensive Care Med. 2007; 22 (6): 319–47. https://doi.org/10.1177/0885066607307506.

13. Khan R.B., Morris E.B., Pui C.H., et al. Long-term outcome and risk factors for uncontrolled seizures after a first seizure in children with hematological malignancies. J Child Neurol. 2014; 29 (6): 774–81. https://doi.org/10.1177/0883073813488675.

14. Caselli D., Ziino O., Bartoli A., et al. Continuous intravenous infusion of lorazepam as seizure prophylaxis in children treated with high-dose busulfan. Bone Marrow Transplant. 2008; 42 (2): 135–6. https://doi.org/10.1038/bmt.2008.91.

15. Tsujimoto S.I., Shirai R., Utano T., et al. Comparison of clonazepam and levetiracetam in children for prevention of busulfan-induced seizure in hematopoietic stem cell transplantation. Int J Hematol. 2020; 111 (3): 463–6. https://doi.org/10.1007/s12185-019-02795-8.

16. Della Puppa A., Denaro L., Rossetto M., et al. Postoperative seizure in high grade glioma patients treated with BCNU wafers. A monoinstitutional experience. J Neurooncol. 2011; 105 (2): 275–80. https://doi.org/10.1007/s11060-011-0577-6.

17. Biran N., Rowley S.D., Vesole D.H., et al. A phase i/ii study of escalating doses of bortezomib in conjunction with high-dose melphalan as a conditioning regimen for salvage autologous peripheral blood stem cell transplantation in patients with multiple myeloma. Biol Blood Marrow Transplant. 2016; 22 (12): 2165–71. https://doi.org/10.1016/j.bbmt.2016.08.017.

18. Ryan S.A., Maceneaney P., O'Reilly S.P., et al. Reversible posterior leukoencephalopathy induced by carboplatin and etoposide. Med Oncol. 2012; 29 (2): 1287–91. https://doi.org/10.1007/s12032-011-9898-8.

19. Kushner B.H., Cheung N.K., Kramer K., et al. Topotecan combined with myeloablative doses of thiotepa and carboplatin for neuroblastoma, brain tumors, and other poor-risk solid tumors in children and young adults. Bone Marrow Transplant. 2001; 28 (6): 551–6. https://doi.org/10.1038/sj.bmt.1703213.

20. Beitinjaneh A., McKinney A.M., Cao Q., Weisdorf D.J. Toxic leukoencephalopathy following fludarabine-associated hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2011; 17 (3): 300–8. https://doi.org/10.1016/j.bbmt.2010.04.003.

21. Meldgaard Knudsen L., Jensen L., Gaarsdal E., et al. A comparative study of sequential priming and mobilisation of progenitor cells with rhG-CSF alone and high-dose cyclophosphamide plus rhG-CSF. Bone Marrow Transplant. 2000; 26 (7): 717–22. https://doi.org/10.1038/sj.bmt.1702609.

22. Hwang S.B., Lee H.Y., Kim H.Y., et al. Life-threatening acute hyponatremia with generalized seizure induced by low-dose cyclophosphamide in a patient with breast cancer. J Breast Cancer. 2011; 14 (4): 345–8. https://doi.org/10.4048/jbc.2011.14.4.345.

23. Kawakami K., Ito R., Kageyama Y., et al. Superior sagittal sinus thrombosis after intrathecal chemotherapy and intravenous high-dose cytarabine in an acute myeloid leukemia case with t(8;21)(q22;q22). Rinsho Ketsueki. 2016; 57 (4): 477–82 (in Japanese). https://doi.org/10.11406/rinketsu.57.477.

24. Bauwens D., Hantson P., Laterre P.F., et al. Recurrent seizure and sustained encephalopathy associated with dimethylsulfoxidepreserved stem cell infusion. Leukemia&Lymphoma. 2005; 46 (11): 1671–4. https://doi.org/10.1080/10428190500235611.

25. Maral S., Albayrak M., Pala C., et al. Dimethyl sulfoxide-induced tonic-clonic seizure and cardiac arrest during infusion of autologous peripheral blood stem cells. Cell Tissue Bank. 2018; 19 (4): 831–2. https://doi.org/10.1007/s10561-018-9718-x.

26. Hequet O., Dumontet C., El Jaafari-Corbin A., et al. Epileptic seizures after autologous peripheral blood progenitor infusion in a patient treated with high-dose chemotherapy for myeloma. Bone Marrow Transplant. 2002; 29 (6): 544. https://doi.org/10.1038/sj.bmt.1703383.

27. Inaba H., Khan R.B., Laningham F.H., et al. Clinical and radiological characteristics of methotrexate-induced acute encephalopathy in pediatric patients with cancer. Ann Oncol. 2008; 19 (1): 178–84. https://doi.org/10.1093/annonc/mdm466.

28. Rao R.D., Swanson J.W., Dejesus R.S., et al. Methotrexate induced seizures associated with acute reversible magnetic resonance imaging (MRI) changes in a patient with acute lymphoblastic leukemia. Leuk Lymphoma. 2002; 43 (6): 1333–6. https://doi.org/10.1080/10428190290026402.

29. Abraham P., Longardner K., Chen P., et al. Case 279: central-variant posterior reversible encephalopathy syndrome. Radiology. 2020; 296 (1): 239–43. https://doi.org/10.1148/radiol.2020181547.

30. Teimouri A., Ahmadi S.R., Anavri Ardakani S., Foroughian M. Cyclosporine-A-based immunosuppressive therapy-induced neurotoxicity: a case report. Open Access Emerg Med. 2020; 2000 (12): 93–7. https://doi.org/10.2147/OAEM.S241501.

31. He W., Chen J., Wang Y.Y., et. al. Sirolimus improves seizure control in pediatric patients with tuberous sclerosis: a prospective cohort study. Seizure. 2020; 79: 20–6. https://doi.org/10.1016/j.seizure.2020.03.018.

32. Xie M., Rao W., Sun L.Y., et al. Tacrolimus-related seizure after pediatric liver transplantation – a single-center experience. Pediatr Transplant. 2014; 18 (1): 58–63. https://doi.org/10.1111/petr.12198.

33. Sevmis S., Karakayali H., Emiroglu R., et al. Tacrolimus-related seizure in the early postoperative period after liver transplantation. Transplant Proc. 2007; 39 (4): 1211–3. https://doi.org/10.1016/j.transproceed.2007.02.049.

34. Vesole A.S., Nagahama Y., Granner M.A., et al. Drug-resistant epilepsy development following stem cell transplant and cyclosporine neurotoxicity induced seizures: case report in an adult and analysis of reported cases in the literature. Epilepsy Behav Case Rep. 2018; 10: 8–13. https://doi.org/10.1016/j.ebcr.2018.01.002.

35. Kadish N.E., Riedel C., Stephani U., Wiegand G. Developmental outcomes in children/adolescents and one adult with tuberous sclerosis complex (TSC) and refractory epilepsy treated with everolimus. Epilepsy Behav. 2020; 111: 107182. https://doi.org/10.1016/j.yebeh.2020.107182.

36. Hung J.J., Huang J.L. Etanercept therapy in children with juvenile rheumatoid arthritis. J Microbiol Immunol Infect. 2005; 38 (6): 444–6.

37. Cannon J.P., Lee T.A., Clark N.M., et al. The risk of seizures among the carbapenems: a meta-analysis. J Antimicrob Chemother. 2014; 69 (8): 2043–55. https://doi.org/10.1093/jac/dku111.

38. Conley T.E., Mohiuddin A., Naz N. Severe co-trimoxazole-induced hypoglycaemia in a patient with microscopic polyangiitis. BMJ Case Rep. 2017; 2017: bcr2016218976. https://doi.org/10.1136/bcr-2016-218976.

39. Balkan I.I., Delil S., Karabacak E.R., et al. Linezolid-induced complex partial seizure in a patient without epilepsy. Int J Infect Dis. 2015; 35: 120. https://doi.org/10.1016/j.ijid.2015.05.007.

40. Lin C.S., Cheng C.J., Chou C.H., Lin S.H. Piperacillin/tazobactaminduced seizure rapidly reversed by high flux hemodialysis in a patient on peritoneal dialysis. Am J Med Sci. 2007; 333 (3): 181–4. https://doi.org/10.1097/MAJ.0b013e31803195e7.

41. Chow K.M., Szeto C.C., Hui A.C., et al. Retrospective review of neurotoxicity induced by cefepime and ceftazidime. Pharmacotherapy. 2003; 23 (3): 369–73. https://doi.org/10.1592/phco.23.3.369.32100.

42. Grill M.F., Maganti R. Cephalosporin-induced neurotoxicity: clinical manifestations, potential pathogenic mechanisms, and the role of electroencephalographic monitoring. Ann Pharmacother. 2008; 42 (12): 1843–50. https://doi.org/10.1345/aph.1L307.

43. Agbaht K., Bitik B., Piskinpasa S., et al. Ciprofloxacin-associated seizures in a patient with underlying thyrotoxicosis: case report and literature review. Int J Clinl Pharmacol Ther. 2009; 47 (5): 303–10. https://doi.org/10.5414/cpp47303.

44. Barton T.L., Roush M.K., Dever L.L. Seizures associated with ganciclovir therapy. Pharmacotherapy. 1992; 12 (5): 413–5.

45. Foroughinia F., Baniasadi S., Seifi S., Fahimi F. Vincristine-induced seizure potentiated by itraconazole following RCHOP chemotherapy for diffuse large B-cell lymphoma. Curr Drug Saf. 2012; 7 (5): 372–4. https://doi.org/10.2174/157488612805076633.

46. Hamdy D.A., El-Geed H., El-Salem S., Zaidan M. Posaconazolevincristine coadministration triggers seizure in a young female adult: a case report. Case Rep Hematol. 2012; 2012: 343742. https://doi.org/10.1155/2012/343742.

47. Beghi E., Carpio A., Forsgren L., et al. Recommendation for a definition of acute symptomatic seizure. Epilepsia. 2010; 51 (4): 671–5. https://doi.org/10.1111/j.1528-1167.2009.02285.x.

48. Common Terminology Criteria for Adverse Events (CTCAE). URL: https://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_8.5x11.pdf (дата обращения 02.04.2021).

49. Saner F., Gu Y., Minouchehr S., et al. Neurological complications after cadaveric and living donor liver transplantation. J Neurol. 2006; 253 (5): 612–7. https://doi.org/10.1007/s00415-006-0069-3.

50. Forgacs B., Merhav H.J., Lappin J., Mieles L. Successful conversion to rapamycin for calcineurin inhibitor-related neurotoxicity following liver transplantation. Transplant Proc. 2005; 37 (4): 1912–4. https://doi.org/10.1016/j.transproceed.2005.02.101.

51. Shuto H., Kataoka Y., Fujisaki K., et al. Inhibition of GABA system involved in cyclosporine-induced convulsions. Life Sci. 1999; 65 (9): 879–87. https://doi.org/10.1016/s0024-3205(99)00318-5.

52. Klawitter J., Gottschalk S., Hainz C., et al. Immunosuppressant neurotoxicity in rat brain models: oxidative stress and cellular metabolism. Chem Res Toxicol. 2010; 23 (3): 608–19. https://doi.org/10.1021/tx900351q.

53. Katsarou A.M., Moshé S.L., Galanopoulou A.S. Interneuronopathies and their role in early life epilepsies and neurodevelopmental disorders. Epilepsia Open. 2017; 2 (3): 284–306. https://doi.org/10.1021/tx900351q10.1002/epi4.12062.

54. Wong M., Yamada K.A. Cyclosporine induces epileptiform activity in an in vitro seizure model. Epilepsia. 2000; 41 (3): 271–6. https://doi.org/10.1111/j.1528-1157.2000.tb00155.x.

55. Li Y., Wang H., Han D., et al. Acute symptomatic seizure due to tacrolimus-related encephalopathy after liver transplantation: two case reports. J Int Med Res. 2019; 47 (12): 6397–403. https://doi.org/10.1177/0300060519883750.

56. Savolainen H., Tenhunen R. Inhibition of heme synthase in brain and liver by low-level peroral sulfite exposure. Res Commun Chem Pathol Pharmacol. 1982; 36 (3): 511–4.

57. Chen-Plotkin A.S., Vossel K.A., Samuels M.A., Chen M.H. Encephalopathy, stroke, and myocardial infarction with DMSO use in stem cell transplantation. Neurology. 2007; 68 (11): 859–61. https://doi.org/10.1212/01.wnl.0000256716.04218.5b.

58. Ruiz-Delgado G.J., Mancías-Guerra C., Tamez-Gómez E.L., et al. Dimethyl sulfoxide-induced toxicity in cord blood stem cell transplantation: report of three cases and review of the literature. Acta Haematol. 2009; 122 (1): 1–5. https://doi.org/10.1159/000227267.

59. Pillinger K.E., Bouchard J., Withers S.T., et al. Inpatient Antibiotic Stewardship Interventions in the adult oncology and hematopoietic stem cell transplant population: a review of the literature. Ann Pharmacother. 2020; 54 (6): 594–10. https://doi.org/10.1177/1060028019890886.

60. Rival M., Chetioui A., Tailland M., Renard D. Linezolid-induced status epilepticus. Acta Neurol Belg. 2020; 120 (5): 1231–2. https://doi.org/10.1007/s13760-020-01333-2.

61. Bora I., Demir A.B., Uzun P. Nonconvulsive status epilepticus cases arising in connection with cephalosporins. Epilepsy Behav Case Rep. 2016; 6: 23–7. https://doi.org/10.1016/j.ebcr.2016.04.005.

62. Meyer M.A. Myoclonic jerks secondary to piperacillin and nafcillin. Neurol Int. 2014; 6 (2): 5349. https://doi.org/10.4081/ni.2014.5349.

63. Jang J.H., Song K.S., Bang J.S., et al. What should be considered to cause the early post-craniotomy seizure: antibiotics (cefazolin) irrigation. J Korean Neurosurg Soc. 2015; 58 (5): 462–6. https://doi.org/10.3340/jkns.2015.58.5.462.

64. McCune J.S., Wang T., Bo-Subait K., et al. Association of antiepileptic medications with outcomes after allogeneic hematopoietic cell transplantation with busulfan/cyclophosphamide conditioning. Biol Blood Marrow Transplant. 2019; 25 (7): 1424–31. https://doi.org/10.1016/j.bbmt.2019.03.001.

65. Nardone R., Brigo F., Trinka E. Acute symptomatic seizures caused by electrolyte disturbances. J Clin Neurol. 2016; 12 (1): 21–33. https://doi.org/10.3988/jcn.2016.12.1.21.

66. Schwartzkroin P.A., Baraban S.C., Hochman D.W. Osmolarity, ionic flux, and changes in brain excitability. Epilepsy Res. 1998; 32 (1-2): 275–85. https://doi.org/10.1016/s0920-1211(98)00058-8.

67. Filippatos T.D., Milionis H.J., Elisaf M.S. Alterations in electrolyte equilibrium in patients with acute leukemia. Eur J Haematol. 2005; 75 (6): 449–60. https://doi.org/10.1111/j.1600-0609.2005.00547.x.

68. Anandan A., Kolk M., Ferrari N., et al. Serum electrolyte dynamics in multiple myeloma patients undergoing autologous haematopoietic stem cell transplantation. Nephrology (Carlton). 2020; 25 (6): 450–6. https://doi.org/10.1111/nep.13712.

69. Milionis H.J., Bourantas C.L., Siamopoulos K.C., et al. Acid-base and electrolyte abnormalities in patients with acute leukemia. Am J Hematol. 1999; 62 (4): 201–7. https://doi.org/10.1002/(sici)1096-8652(199912)62:4<201::aid-ajh1>3.0.co;2-1.

70. Philibert D., Desmeules S., Filion A., et al. Incidence and severity of early electrolyte abnormalities following autologous haematopoietic stem cell transplantation. Nephrol Dial Transplant. 2008; 23 (1): 359–63. https://doi.org/10.1093/ndt/gfm571.

71. Van Amelsvoort T., Bakshi R., Devaux C.B., Schwabe S. Hyponatremia associated with carbamazepine and oxcarbazepine therapy: a review. Epilepsia. 1994; 35 (1): 181–8. https://doi.org/10.1111/j.1528-1157.1994.tb02930.x.

72. de Leeuw D.C., Kooter A.J. Transient seizure-induced sodium increase camouflaging a symptomatic hyponatremia. BMJ Case Rep. 2020; 13 (1): e229328. https://doi.org/10.1136/bcr-2019-229328.

73. Pilato F., Distefano M., Calandrelli R. Posterior reversible encephalopathy syndrome and reversible cerebral vasoconstriction syndrome: clinical and radiological considerations. Front Neurol. 2020; 11: 34. https://doi.org/10.3389/fneur.2020.00034.

74. Chen Q., Zhao X., Fu H.X., et al. Posterior reversible encephalopathy syndrome (PRES) after haploidentical haematopoietic stem cell transplantation: incidence, risk factors and outcomes. Bone Marrow Transplant. 2020; 55 (10): 2035–42. https://doi.org/10.1038/s41409-020-0894-5.

75. Datar S., Singh T., Rabinstein A.A., et al. Long-term risk of seizures and epilepsy in patients with posterior reversible encephalopathy syndrome. Epilepsia. 2015; 56 (4): 564–8. https://doi.org/10.1111/epi.12933.

76. Hammerstrom A.E., Howell J., Gulbis A., et al. Tacrolimus-associated posterior reversible encephalopathy syndrome in hematopoietic allogeneic stem cell transplantation. Am J Hematol. 2013; 88 (4): 301–5. https://doi.org/10.1002/ajh.23402.

77. Gaziev J., Marziali S., Paciaroni K., et al. Posterior reversible encephalopathy syndrome after hematopoietic cell transplantation in children with hemoglobinopathies. Biol Blood Marrow Transpl. 2017; 23 (9): 1531–40. https://doi.org/10.1016/j.bbmt.2017.05.033.

78. April D., Lall N., Steven A. Stroke-like migraine attacks after radiation therapy syndrome. Ochsner J. 2020; 20 (1): 6–9. https://doi.org/10.31486/toj.19.0090.

79. Kerklaan J.P., Lycklama á Nijeholt G.J., Wiggenraad R.G., et al. SMART syndrome: a late reversible complication after radiation therapy for brain tumours. J Neurol. 2011; 258 (6): 1098–104. https://doi.org/10.1007/s00415-010-5892-x.

80. Farid K., Meissner W.G., Samier-Foubert A., et al. Normal cerebrovascular reactivity in stroke-like migraine attacks after radiation therapy syndrome. Clin Nucl Med. 2010; 35 (8): 583–5. https://doi.org/10.1097/RLU.0b013e3181e4db6f.

81. Suarez Montero J.C., Caballero Gonzalez A.C., Martín Aguilar L., Mancebo Cortés J. Immune effector cell-associated neurotoxicity syndrome: a therapeutic approach in the critically ill. Med Intensiva. 2020: S0210-5691(20)30244-8. https://doi.org/10.1016/j.medin.2020.06.014.

82. Perrin P., Collongues N., Baloglu S., et al. Cytokine release syndromeassociated encephalopathy in patients with COVID-19. Eur J Neurol. 2021; 28 (1): 248–58. https://doi.org/10.1111/ene.14491.

83. Borrega J.G., Gödel P., Rüger M.A., et al. In the eye of the storm: immune-mediated toxicities associated with CAR-T cell therapy. Hemasphere. 2019; 3 (2): e191. https://doi.org/10.1097/HS9.0000000000000191.

84. Gust J., Finney O.C., Li D., et al. Glial injury in neurotoxicity after pediatric CD19-directed chimeric antigen receptor T cell therapy. Ann Neurol. 2019; 86 (1): 42–54. https://doi.org/10.1002/ana.25502.

85. Gust J., Hay K.A., Hanafi L.A., et al. Endothelial activation and blood-brain barrier disruption in neurotoxicity after adoptive immunotherapy with CD19 CAR-T cells. Cancer Discov. 2017; 7 (12): 1404–9. https://doi.org/10.1158/2159-8290.CD-17-0698.

86. Zheng W. Neurotoxicology of the brain barrier system: new implications. J Toxicol Clin Toxicol. 2001; 39 (7): 711–9. https://doi.org/10.1081/clt-100108512.

87. Martell R.W., Sher C., Jacobs P., Monteagudo F. High-dose busulfan and myoclonic epilepsy. Ann Intern Med. 1987; 106 (1): 173. https://doi.org/10.7326/0003-4819-106-1-173_1.

88. Janssen S., Bloem B.R., van de Warrenburg B.P. The clinical heterogeneity of drug-induced myoclonus: an illustrated review. J Neurol. 2017; 264 (8): 1559–66. https://doi.org/10.1007/s00415-016-8357-z.

89. Dowling M.R., Li S., Dey B.R., et al. Neurologic complications after allogeneic hematopoietic stem cell transplantation: risk factors and impact. Bone Marrow Transplant. 2018; 53 (2): 199–206. https://doi.org/10.1038/bmt.2017.239.

90. Hamidieh A.A., Hamedani R., Hadjibabaie M., et al. Oral lorazepam prevents seizure during high-dose busulfan in children undergoing hematopoietic stem cell transplantation: a prospective study. Pediatr Hematol Oncol. 2010; 27 (7): 529–33. https://doi.org/10.3109/08880018.2010.496895.

91. Ruiz-Argüelles G.J., Gomez-Almaguer D., Steensma D.P. Outdated dogma? Busulfan, seizure prophylaxis, and stem cell allografting. Am J Hematol. 2012; 87 (9): 941. https://doi.org/10.1002/ajh.23270.

92. Diaz-Carrasco M.S., Olmos R., Blanquer M., et al. Clonazepam for seizure prophylaxis in adult patients treated with high dose busulfan. Int J Clin Pharm. 2013; 35 (3): 339–43. https://doi.org/10.1007/s11096-013-9768-x.

93. Chan K.W., Mullen C.A., Worth L.L., et al. Lorazepam for seizure prophylaxis during high-dose busulfan administration. Bone Marrow Transplant. 2002; 29 (12): 963–5. https://doi.org/10.1038/sj.bmt.1703593.

94. Hassan M., Oberg G., Björkholm M., et al. Influence of prophylactic anticonvulsant therapy on high-dose busulphan kinetics. Cancer Chemother Pharmacol. 1993; 33 (3): 181–6. https://doi.org/10.1007/BF00686213.

95. Carreras E., Cahn J.Y., Puozzo C., et al. Influence on Busilvex pharmacokinetics of clonazepam compared to previous phenytoin historical data. Anticancer Res. 2010; 30 (7): 2977–84.

96. Chaguaceda C., Aguilera-Jiménez V., Gutierrez G., et al. Oral levetiracetam for prevention of busulfan-induced seizures in adult hematopoietic cell transplant. Int J Clin Pharm. 2020; 42 (2): 351–4. https://doi.org/10.1007/s11096-020-00977-7.

97. Floeter A.E., Mccune J.S. Levetiracetam for the prevention of busulfan-induced seizures in pediatric hematopoietic cell transplantation recipients. J Oncol Pharm Pract. 2017; 23 (5). https://doi.org/10.1177/1078155216651128.

98. Eberly A.L., Anderson G.D., Bubalo J.S., McCune J.S. Optimal prevention of seizures induced by high-dose busulfan. Pharmacotherapy. 2008; 28 (12): 1502–10. https://doi.org/10.1592/phco.28.12.1502.

99. Marcus R.E., Goldman J.M. Convulsions due to high-dose busulphan. Lancet. 1984; 2 (8417-8418): 1463. https://doi.org/10.1016/s0140-6736(84)91649-0.

100. Vassal G., Deroussent A., Hartmann O., et al.. Dose-dependent neurotoxicity of high-dose busulfan in children: a clinical and pharmacological study. Cancer Res. 1990; 50 (19): 6203–7.

101. Woodward S. Management of faecal incontinence in graft-versus-host disease. Br J Nurs. 2012; 21 (2): 84–8. https://doi.org/10.12968/bjon.2012.21.2.84.